First malaria drug for babies is approved in ‘major public health milestone’

The approval of Coartem Baby represents a critical advancement in public health, particularly in regions heavily burdened by malaria. By providing a safe treatment option for infants, this drug could significantly reduce the number of deaths among the most vulnerable populations. The focus on newborns highlights a shift in malaria treatment strategies, which have traditionally overlooked this age group. As malaria remains a leading cause of child mortality in Africa, the implications of this approval could be profound.